NCT05996835: Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) |
|
|
| Recruiting | 2 | 320 | Europe, Canada, Japan, US, RoW | TIN816 70 mg lyophilisate powder, Placebo | Novartis Pharmaceuticals | Acute Kidney Injury Due to Sepsis | 12/25 | 02/26 | | |
NCT05996835: Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (SA-AKI) |
|
|
| Recruiting | 2 | 320 | Europe, Canada, Japan, US, RoW | TIN816 70 mg lyophilisate powder, Placebo | Novartis Pharmaceuticals | Acute Kidney Injury Due to Sepsis | 12/25 | 02/26 | | |